Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis
Background and aims Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited. In this study, we evaluated the impact of IGB pl...
Gespeichert in:
| Veröffentlicht in: | Liver international 2021-09, Vol.41 (9), p.2112-2116 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2116 |
|---|---|
| container_issue | 9 |
| container_start_page | 2112 |
| container_title | Liver international |
| container_volume | 41 |
| creator | Salomone, Federico Currenti, Walter Magrì, Giovanni Boškoski, Ivo Zelber‐Sagi, Shira Galvano, Fabio |
| description | Background and aims
Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited. In this study, we evaluated the impact of IGB placement in NAFLD patients with advanced fibrosis.
Methods
We retrospectively assessed the effects of the Orbera™ fluid‐filled IGB in a cohort of obese patients with liver stiffness ≥9.7 kPa (corresponding to F3‐F4). Patients with endoscopic signs of portal hypertension were excluded. Changes in metabolic and liver parameters from baseline to follow‐up (6 mo) were assessed.
Results
A total of 26 obese patients, aged 53 [44 ‐ 62] years, with BMI 35.1 ± 4.7 kg/m2 were included. All patients achieved a significant body weight loss (106 ± 19.7 vs. 92 ± 18.3 kg, P |
| doi_str_mv | 10.1111/liv.14917 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2521496681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2561532774</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-165a279fb38cd0ef59ad56c80c42dbe5a738814b0c324a580b987c87a8c62ba33</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgitXqwheQgBtd1OYymWSWUrwUCm7U7XAmk2hKOqnJtKVvb7TqQjCbhMPHH86P0Bkl1zSfsXfra1pUVO6hI1pINeKM0_3fN-MDdJzSnBBaVYIeogHnFVclJ0fo9dZao_uEg8Wu6yO8Quqj07gB70Po8hAvoXemy2bj-jfchQ68Dm_BZ2Wh77c4_28ibl0ykAyGrsXQrqHTpsXWNTEkl07QgQWfzOn3PUTPd7dPk4fR7PF-OrmZjTQXXI5oKYDJyjZc6ZYYKypoRakV0QVrGyNAcqVo0RDNWQFCkaZSUisJSpesAc6H6HKXu4zhfWVSXy9c0sZ76ExYpZoJlpsqS0UzvfhD52EV83KfqqSCMymLrK52Suc9UjS2Xka3gLitKak_26_z9vVX-9mefyeumoVpf-VP3RmMd2DjvNn-n1TPpi-7yA8wk48A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561532774</pqid></control><display><type>article</type><title>Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis</title><source>Access via Wiley Online Library</source><creator>Salomone, Federico ; Currenti, Walter ; Magrì, Giovanni ; Boškoski, Ivo ; Zelber‐Sagi, Shira ; Galvano, Fabio</creator><creatorcontrib>Salomone, Federico ; Currenti, Walter ; Magrì, Giovanni ; Boškoski, Ivo ; Zelber‐Sagi, Shira ; Galvano, Fabio</creatorcontrib><description><![CDATA[Background and aims
Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited. In this study, we evaluated the impact of IGB placement in NAFLD patients with advanced fibrosis.
Methods
We retrospectively assessed the effects of the Orbera™ fluid‐filled IGB in a cohort of obese patients with liver stiffness ≥9.7 kPa (corresponding to F3‐F4). Patients with endoscopic signs of portal hypertension were excluded. Changes in metabolic and liver parameters from baseline to follow‐up (6 mo) were assessed.
Results
A total of 26 obese patients, aged 53 [44 ‐ 62] years, with BMI 35.1 ± 4.7 kg/m2 were included. All patients achieved a significant body weight loss (106 ± 19.7 vs. 92 ± 18.3 kg, P < .001) and waist circumference reduction (116 ± 13.3 vs. 104 ± 13.4 kg, P < .001) at 6‐month follow‐up after IGB placement. Weight loss induced by IGB lowered blood glucose (140 [112; 169] vs. 118 [94; 144] mg/dl, P < .01), glycated hemoglobin (7.5 ± 1.3 vs. 6.6 ± 1.2%, P < .001), FIB‐4 (3.2 ± 0.7 vs. 2.7 ± 0.8, P < .001), liver stiffness (13.3 ± 3.2 vs. 11.3 ± 2.8 kPa, P < .001) and controlled attenuation parameter (355 [298‐400] vs. 296 [255‐352] dB/m, P < .01). Gastroesophageal reflux symptoms were common, but no severe adverse event was observed.
Conclusion
Obese patients with advanced liver fibrosis, treated with 6‐month IGB, can achieve regression of fibrosis as assessed by reduction of liver stiffness and FIB‐4. Randomized controlled trials are needed to confirm these findings.]]></description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.14917</identifier><identifier>PMID: 33938630</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adverse events ; Attenuation ; Balloon treatment ; Body weight ; Body weight loss ; Clinical trials ; Endoscopy ; Fatty liver ; Fibrosis ; Gastroesophageal reflux ; Hemoglobin ; Hypertension ; intragastric balloon ; Liver ; Liver diseases ; liver stiffness ; NAFLD ; obesity ; Parameters ; Placement ; Reduction ; Signs and symptoms ; Stiffness ; Weight loss</subject><ispartof>Liver international, 2021-09, Vol.41 (9), p.2112-2116</ispartof><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2021 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-165a279fb38cd0ef59ad56c80c42dbe5a738814b0c324a580b987c87a8c62ba33</citedby><cites>FETCH-LOGICAL-c3537-165a279fb38cd0ef59ad56c80c42dbe5a738814b0c324a580b987c87a8c62ba33</cites><orcidid>0000-0001-5264-2935 ; 0000-0002-1324-7497</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.14917$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14917$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33938630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salomone, Federico</creatorcontrib><creatorcontrib>Currenti, Walter</creatorcontrib><creatorcontrib>Magrì, Giovanni</creatorcontrib><creatorcontrib>Boškoski, Ivo</creatorcontrib><creatorcontrib>Zelber‐Sagi, Shira</creatorcontrib><creatorcontrib>Galvano, Fabio</creatorcontrib><title>Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis</title><title>Liver international</title><addtitle>Liver Int</addtitle><description><![CDATA[Background and aims
Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited. In this study, we evaluated the impact of IGB placement in NAFLD patients with advanced fibrosis.
Methods
We retrospectively assessed the effects of the Orbera™ fluid‐filled IGB in a cohort of obese patients with liver stiffness ≥9.7 kPa (corresponding to F3‐F4). Patients with endoscopic signs of portal hypertension were excluded. Changes in metabolic and liver parameters from baseline to follow‐up (6 mo) were assessed.
Results
A total of 26 obese patients, aged 53 [44 ‐ 62] years, with BMI 35.1 ± 4.7 kg/m2 were included. All patients achieved a significant body weight loss (106 ± 19.7 vs. 92 ± 18.3 kg, P < .001) and waist circumference reduction (116 ± 13.3 vs. 104 ± 13.4 kg, P < .001) at 6‐month follow‐up after IGB placement. Weight loss induced by IGB lowered blood glucose (140 [112; 169] vs. 118 [94; 144] mg/dl, P < .01), glycated hemoglobin (7.5 ± 1.3 vs. 6.6 ± 1.2%, P < .001), FIB‐4 (3.2 ± 0.7 vs. 2.7 ± 0.8, P < .001), liver stiffness (13.3 ± 3.2 vs. 11.3 ± 2.8 kPa, P < .001) and controlled attenuation parameter (355 [298‐400] vs. 296 [255‐352] dB/m, P < .01). Gastroesophageal reflux symptoms were common, but no severe adverse event was observed.
Conclusion
Obese patients with advanced liver fibrosis, treated with 6‐month IGB, can achieve regression of fibrosis as assessed by reduction of liver stiffness and FIB‐4. Randomized controlled trials are needed to confirm these findings.]]></description><subject>Adverse events</subject><subject>Attenuation</subject><subject>Balloon treatment</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Clinical trials</subject><subject>Endoscopy</subject><subject>Fatty liver</subject><subject>Fibrosis</subject><subject>Gastroesophageal reflux</subject><subject>Hemoglobin</subject><subject>Hypertension</subject><subject>intragastric balloon</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>liver stiffness</subject><subject>NAFLD</subject><subject>obesity</subject><subject>Parameters</subject><subject>Placement</subject><subject>Reduction</subject><subject>Signs and symptoms</subject><subject>Stiffness</subject><subject>Weight loss</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10MtKAzEUBuAgitXqwheQgBtd1OYymWSWUrwUCm7U7XAmk2hKOqnJtKVvb7TqQjCbhMPHH86P0Bkl1zSfsXfra1pUVO6hI1pINeKM0_3fN-MDdJzSnBBaVYIeogHnFVclJ0fo9dZao_uEg8Wu6yO8Quqj07gB70Po8hAvoXemy2bj-jfchQ68Dm_BZ2Wh77c4_28ibl0ykAyGrsXQrqHTpsXWNTEkl07QgQWfzOn3PUTPd7dPk4fR7PF-OrmZjTQXXI5oKYDJyjZc6ZYYKypoRakV0QVrGyNAcqVo0RDNWQFCkaZSUisJSpesAc6H6HKXu4zhfWVSXy9c0sZ76ExYpZoJlpsqS0UzvfhD52EV83KfqqSCMymLrK52Suc9UjS2Xka3gLitKak_26_z9vVX-9mefyeumoVpf-VP3RmMd2DjvNn-n1TPpi-7yA8wk48A</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Salomone, Federico</creator><creator>Currenti, Walter</creator><creator>Magrì, Giovanni</creator><creator>Boškoski, Ivo</creator><creator>Zelber‐Sagi, Shira</creator><creator>Galvano, Fabio</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5264-2935</orcidid><orcidid>https://orcid.org/0000-0002-1324-7497</orcidid></search><sort><creationdate>202109</creationdate><title>Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis</title><author>Salomone, Federico ; Currenti, Walter ; Magrì, Giovanni ; Boškoski, Ivo ; Zelber‐Sagi, Shira ; Galvano, Fabio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-165a279fb38cd0ef59ad56c80c42dbe5a738814b0c324a580b987c87a8c62ba33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Attenuation</topic><topic>Balloon treatment</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Clinical trials</topic><topic>Endoscopy</topic><topic>Fatty liver</topic><topic>Fibrosis</topic><topic>Gastroesophageal reflux</topic><topic>Hemoglobin</topic><topic>Hypertension</topic><topic>intragastric balloon</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>liver stiffness</topic><topic>NAFLD</topic><topic>obesity</topic><topic>Parameters</topic><topic>Placement</topic><topic>Reduction</topic><topic>Signs and symptoms</topic><topic>Stiffness</topic><topic>Weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salomone, Federico</creatorcontrib><creatorcontrib>Currenti, Walter</creatorcontrib><creatorcontrib>Magrì, Giovanni</creatorcontrib><creatorcontrib>Boškoski, Ivo</creatorcontrib><creatorcontrib>Zelber‐Sagi, Shira</creatorcontrib><creatorcontrib>Galvano, Fabio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salomone, Federico</au><au>Currenti, Walter</au><au>Magrì, Giovanni</au><au>Boškoski, Ivo</au><au>Zelber‐Sagi, Shira</au><au>Galvano, Fabio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2021-09</date><risdate>2021</risdate><volume>41</volume><issue>9</issue><spage>2112</spage><epage>2116</epage><pages>2112-2116</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract><![CDATA[Background and aims
Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited. In this study, we evaluated the impact of IGB placement in NAFLD patients with advanced fibrosis.
Methods
We retrospectively assessed the effects of the Orbera™ fluid‐filled IGB in a cohort of obese patients with liver stiffness ≥9.7 kPa (corresponding to F3‐F4). Patients with endoscopic signs of portal hypertension were excluded. Changes in metabolic and liver parameters from baseline to follow‐up (6 mo) were assessed.
Results
A total of 26 obese patients, aged 53 [44 ‐ 62] years, with BMI 35.1 ± 4.7 kg/m2 were included. All patients achieved a significant body weight loss (106 ± 19.7 vs. 92 ± 18.3 kg, P < .001) and waist circumference reduction (116 ± 13.3 vs. 104 ± 13.4 kg, P < .001) at 6‐month follow‐up after IGB placement. Weight loss induced by IGB lowered blood glucose (140 [112; 169] vs. 118 [94; 144] mg/dl, P < .01), glycated hemoglobin (7.5 ± 1.3 vs. 6.6 ± 1.2%, P < .001), FIB‐4 (3.2 ± 0.7 vs. 2.7 ± 0.8, P < .001), liver stiffness (13.3 ± 3.2 vs. 11.3 ± 2.8 kPa, P < .001) and controlled attenuation parameter (355 [298‐400] vs. 296 [255‐352] dB/m, P < .01). Gastroesophageal reflux symptoms were common, but no severe adverse event was observed.
Conclusion
Obese patients with advanced liver fibrosis, treated with 6‐month IGB, can achieve regression of fibrosis as assessed by reduction of liver stiffness and FIB‐4. Randomized controlled trials are needed to confirm these findings.]]></abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33938630</pmid><doi>10.1111/liv.14917</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5264-2935</orcidid><orcidid>https://orcid.org/0000-0002-1324-7497</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2021-09, Vol.41 (9), p.2112-2116 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2521496681 |
| source | Access via Wiley Online Library |
| subjects | Adverse events Attenuation Balloon treatment Body weight Body weight loss Clinical trials Endoscopy Fatty liver Fibrosis Gastroesophageal reflux Hemoglobin Hypertension intragastric balloon Liver Liver diseases liver stiffness NAFLD obesity Parameters Placement Reduction Signs and symptoms Stiffness Weight loss |
| title | Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T09%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20intragastric%20balloon%20in%20patients%20with%20nonalcoholic%20fatty%20liver%20disease%20and%20advanced%20fibrosis&rft.jtitle=Liver%20international&rft.au=Salomone,%20Federico&rft.date=2021-09&rft.volume=41&rft.issue=9&rft.spage=2112&rft.epage=2116&rft.pages=2112-2116&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.14917&rft_dat=%3Cproquest_cross%3E2561532774%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561532774&rft_id=info:pmid/33938630&rfr_iscdi=true |